David A. Siegel Innoviva, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Innoviva, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 571,500 shares of INVA stock, worth $12.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

571,500

Previous 204,500 179.46%

Holding current value

$12.1 Million

Previous $3.55 Million 192.02%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$17.21 - $18.98 $6.32 Million - $6.97 Million	367,000 Added 179.46%	571,500 $10.4 Million
Q4 2024 Feb 14, 2025	SELL	$17.35 - $20.32 $3.02 Million - $3.53 Million	-173,800 Reduced 45.94%	204,500 $3.55 Million
Q3 2024 Nov 14, 2024	BUY	$16.33 - $20.04 $344,562 - $422,844	21,100 Added 5.91%	378,300 $7.3 Million
Q2 2024 Aug 14, 2024	SELL	$14.4 - $16.4 $704,160 - $801,959	-48,900 Reduced 12.04%	357,200 $5.86 Million
Q1 2024 May 15, 2024	BUY	$14.56 - $16.78 $2.84 Million - $3.27 Million	195,100 Added 92.46%	406,100 $6.19 Million
Q4 2023 Feb 14, 2024	SELL	$12.32 - $16.27 $193,424 - $255,439	-15,700 Reduced 6.93%	211,000 $3.38 Million
Q3 2023 Nov 14, 2023	BUY	$12.37 - $13.89 $509,643 - $572,268	41,200 Added 22.21%	226,700 $2.94 Million
Q2 2023 Aug 14, 2023	BUY	$11.39 - $13.72 $763,130 - $919,240	67,000 Added 56.54%	185,500 $2.36 Million
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $1.57 Million - $1.99 Million	-146,100 Reduced 55.22%	118,500 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$11.8 - $13.78 $1.49 Million - $1.74 Million	126,500 Added 91.6%	264,600 $3.51 Million
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $3.93 Million - $5.15 Million	-338,100 Reduced 71.0%	138,100 $1.6 Million
Q2 2022 Aug 15, 2022	SELL	$14.32 - $19.88 $1.24 Million - $1.72 Million	-86,300 Reduced 15.34%	476,200 $7.03 Million
Q1 2022 May 16, 2022	BUY	$15.39 - $20.25 $5.51 Million - $7.25 Million	357,900 Added 174.93%	562,500 $10.9 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $18.72 $1.76 Million - $2.07 Million	110,400 Added 117.2%	204,600 $3.53 Million
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $1.23 Million - $1.62 Million	94,200 New	94,200 $1.57 Million
Q3 2020 Nov 16, 2020	SELL	$10.33 - $14.49 $502,389 - $704,706	-48,634 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $238,992 - $317,408	20,800 Added 74.73%	48,634 $680,000
Q1 2020 May 15, 2020	SELL	$8.11 - $15.23 $298,448 - $560,464	-36,800 Reduced 56.94%	27,834 $327,000
Q4 2019 Feb 14, 2020	SELL	$10.28 - $14.38 $429,354 - $600,595	-41,766 Reduced 39.25%	64,634 $915,000
Q3 2019 Nov 14, 2019	SELL	$10.05 - $14.55 $872,681 - $1.26 Million	-86,834 Reduced 44.94%	106,400 $1.12 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $14.95 $740,150 - $844,675	-56,500 Reduced 22.62%	193,234 $2.81 Million
Q1 2019 May 15, 2019	SELL	$13.69 - $20.06 $335,405 - $491,469	-24,500 Reduced 8.93%	249,734 $3.5 Million
Q4 2018 Feb 14, 2019	BUY	$13.96 - $18.26 $1.25 Million - $1.64 Million	89,600 Added 48.53%	274,234 $4.79 Million
Q3 2018 Nov 14, 2018	SELL	$13.63 - $15.7 $576,085 - $663,576	-42,266 Reduced 18.63%	184,634 $2.81 Million
Q2 2018 Aug 14, 2018	BUY	$13.44 - $17.59 $1.09 Million - $1.42 Million	80,966 Added 55.48%	226,900 $3.13 Million
Q1 2018 May 15, 2018	BUY	$13.8 - $16.99 $1.02 Million - $1.25 Million	73,800 Added 102.31%	145,934 $2.43 Million
Q4 2017 Feb 14, 2018	BUY	$11.73 - $14.75 $470,373 - $591,475	40,100 Added 125.18%	72,134 $1.02 Million
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $386,330 - $452,320	32,034	32,034 $452,000

Others Institutions Holding INVA

# of Institutions

256

Shares Held

75M

Call Options Held

2.3K

Put Options Held

2.4K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.48B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account